Patients with community acquired pneumonia exhibit depleted vitamin C status and elevated oxidative stress

Anitra C. Carr 1*, Emma Spencer 1, Liane Dixon 2 and Stephen Chambers 3

1 Nutrition in Medicine Research Group, Department of Pathology and Biomedical Science, University of Otago, Christchurch, 8011, New Zealand; emma.spencer@otago.ac.nz
2 Department of Infectious Diseases, Christchurch Hospital, Christchurch, 8011, New Zealand; liane.dixon@cdhb.health.nz
3 The Infection Group, Department of Pathology and Biomedical Science, University of Otago, Christchurch, 8011, New Zealand; steve.chambers@otago.ac.nz
* Correspondence: anitra.carr@otago.ac.nz; Tel.: (+64) 364 0649.

Abstract: Pneumonia is a severe lower respiratory tract infection that is a common complication and a major cause of mortality of the vitamin C-deficiency disease scurvy. This suggests an important link between vitamin C status and lower respiratory tract infections. Due to the paucity of information on the vitamin C status of patients with pneumonia, we assessed the vitamin C status of 50 patients with community-acquired pneumonia and compared these with 50 healthy community controls. The pneumonia cohort comprised 44 patients recruited through the Acute Medical Assessment Unit (AMAU) and 6 patients recruited through the intensive care unit (ICU); mean age 68 ± 17 years, 54% male. Clinical, microbiological and haematological parameters were recorded. Blood samples were tested for vitamin C status using HPLC with electrochemical detection and protein carbonyl concentrations, a marker of oxidative stress, using ELISA. Patients with pneumonia had depleted vitamin C status compared with healthy controls (23 ± 14 µmol/L vs 56 ± 24 µmol/L, P <0.001). The more severe patients in the ICU had significantly lower vitamin C status than those recruited through AMAU (11 ± 3 µmol/L vs 24 ± 14 µmol/L, P = 0.02). The total pneumonia cohort comprised 62% with hypovitaminosis C and 22% with deficiency, compared with only 8% hypovitaminosis C and no cases of deficiency in the healthy controls. The pneumonia cohort also exhibited significantly elevated protein carbonyl concentrations compared with the healthy controls (P < 0.001), indicating enhanced oxidative stress in the patients. We were able to collect subsequent samples form 28% of the cohort (mean 2.7 ± 1.7 days; range 1–7 days). These showed no significant differences in vitamin C status or protein carbonyl concentrations compared with baseline values (P = 0.6). Overall, the depleted vitamin C status and elevated oxidative stress observed in the patients with pneumonia indicates an enhanced requirement for the vitamin during their illness. Due to the important roles that vitamin C plays in the immune system, low vitamin C status is possibly both a cause and a consequence of the disease. Therefore, these patients would likely benefit from additional vitamin C supplementation to restore their blood and tissue levels to optimal. This may decrease oxidative stress and aid in their recovery.

Keywords: Vitamin C; ascorbic acid; ascorbate; pneumonia; community acquired pneumonia; oxidative stress; protein carbonyls; hypovitaminosis C; vitamin C deficiency

1. Introduction

Pneumonia is a severe lower respiratory tract infection that can be caused by bacterial, fungal and viral pathogens, including the novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) [1, 2]. Lower respiratory tract infections are a leading cause of morbidity and mortality worldwide.
In 2016, lower respiratory tract infections resulted in more than 65 million hospital admissions and nearly 2.4 million deaths worldwide [3]. Mortality is particularly high for children under five and the elderly, which is of concern due to the increasingly aging population [4]. Increased incidence of community-acquired pneumonia is also associated with lower socioeconomic status and certain ethnic groups [4-6].

Pneumonia is a common complication and a major cause of mortality of the vitamin C deficiency disease scurvy, which suggests an important link between vitamin C status and lower respiratory tract infections [7]. The EPIC-Norfolk longitudinal study comprising more than 19,000 men and women has shown a 30% lower risk of pneumonia and a 39% lower mortality from pneumonia for people in the top quartile of vitamin C status (>66 μmol/L, i.e. saturating status), ascertained from a single baseline measurement at enrolment, compared with those in the bottom quartile of vitamin C status (≤41 μmol/L) [8]. Despite vitamin C’s known roles in supporting immune function through acting as an antioxidant and enzyme cofactor [9], surprisingly few studies have explored the link between vitamin C and pneumonia [10]. Two case control studies have indicated that patients with pneumonia have significantly lower vitamin C status than healthy controls, and there was an inverse correlation with the severity of the condition [11, 12]. Two other studies which explored the time course indicated that up to 40% of patients with pneumonia exhibited vitamin C deficiency (i.e. plasma vitamin C concentrations <11 μmol/L) at hospital admission, and concentrations remained low for at least 4 weeks [13, 14].

These studies indicate a higher utilization of, and potentially also a higher requirement for, vitamin C during lower respiratory tract infections. Patients with pneumonia may also have lower baseline vitamin C status which could potentially make them more susceptible to infection. Due to the paucity of recent studies investigating the link between vitamin C and pneumonia, and the global relevance due to periodic outbreaks of SARS-related coronaviruses, we have measured the vitamin C status of patients with community-acquired pneumonia who were admitted to the Acute Medical Assessment Unit or intensive care unit of our public hospital. We also measured protein carbonyl concentrations, as an established marker of oxidative stress. These parameters were compared with those measured in healthy controls.

2. Methods

2.1 Setting and study participants

Christchurch Hospital is the largest tertiary, teaching and research hospital in the South Island of New Zealand; it is located in New Zealand’s second largest city and services 600,000 people in the Canterbury region. A total of 50 patients were recruited for this observational study in Christchurch Hospital: 44 patients with CAP recruited in the Acute Medical Assessment Unit and medical wards (July 2017 to February 2018) and six patients with CAP recruited in the Intensive Care Unit (December 2015 to August 2016). Ethical approval was obtained from the New Zealand Southern Health and Disability Ethics Committee (#16STH235 and #15STH36). Radiology reports for suspected pneumonia were viewed daily to identify potential patients. Many of the patients were elderly and to ensure correct consent process cognition was considered, along with supportive family to discuss this before continuing. All patients signed informed consent documents.

2.2 Inclusion and exclusion criteria.

Community-acquired pneumonia was defined as a pneumonia that had been acquired outside of hospitals or health care settings. Pneumonia was defined in a patient with an acute illness and new inflammatory infiltrate on chest radiograph, or a diagnosis of community-acquired pneumonia by treating physician and the presence of at least one of the following acute respiratory signs and symptoms: cough, increased sputum production, dyspnoea, core body temperature of ≥38.0°C, auscultatory findings of abnormal breathing sounds or rales [15, 16]. Other inclusion criteria were aged ≥18 years and able to provide informed consent. Exclusion criteria were: (1) pneumonia was (a) not the primary cause for hospital admission, (b) an expected terminal event, or (c) distal to bronchial obstruction; (2) patients with tuberculosis or bronchiectasis, (3) patients who had been in hospital
within the previous 14 days, or had previously been entered in the study. Plasma biomarkers were also measured in a cohort of non-fasting healthy community controls who were resident in Christchurch (n = 50, 50% female, aged 57 ± 17 years).

2.2 Disease severity scores

The CURB-65 was calculated from admission recordings using values from the first 12 hours in hospital (range 0-5) to determine severity and predict mortality of pneumonia and was calculated for all patients. The criteria are: Confusion of new onset (defined as an abbreviated mental test score, AMTS, of ≤8), blood Urea nitrogen greater >7 mmol/l, Respiratory rate of ≥30 breaths per minute, Blood pressure <90 mmHg systolic or ≤60 mmHg diastolic, age ≥65 years and each criteria scores 1 point if met [17]. ICU severity scores were recorded if the patients were admitted to the ICU. These were: Acute Physiology and Chronic Health Evaluation II and III (APACHE II and III, range 0-79 and 0-299, respectively); Simplified Acute Physiology Score II (SAPS II, range 0-163); and Sequential Organ Failure Assessment (SOFA, range 0-24). Common comorbidities were also recorded.

2.3 Blood sampling and processing

A blood sample (with heparin anticoagulant) was collected within 24 hours of admission and confirmed pneumonia (chest film). Because these were acutely ill patients, the blood samples were non-fasting. A blood sample was not able to be collected from one participant so their clinical data was excluded from the analysis. A second sample was collected from a subset of the participants on day of discharge (n = 14). The blood samples were placed on ice and immediately transferred to the laboratory for centrifugation to separate plasma for vitamin C and oxidative stress biomarker analysis. An aliquot of the plasma was treated with an equal volume of 0.54 M perchloric acid and 100 µmol/L of the metal chelator DTPA to precipitate protein and stabilize the vitamin C. The supernatant and spare plasma samples were stored at -80°C until analysis.

2.4 Analysis of blood analytes

Routine haematological analyses were carried out at Canterbury Health Laboratories, an International Accreditation New Zealand (IANZ) laboratory. Identified organisms were recorded. The vitamin C content of the processed plasma samples was determined using HPLC with electrochemical detection as described previously [18]. The protein carbonyl content of the plasma was determined using a sensitive ELISA method as described previously [19].

2.5 Statistical analysis

Data are presented as mean and SD or mean and 95% CI as indicated. Statistical analyses were carried out using Excel data analysis add-in and GraphPad Prism 8.0 software (San Diego, USA). Differences between groups were determined using Student’s t-test or Mann-Whitney U test for non-parametric variables. Linear regressions were carried out using Pearson correlations. Statistical significance was set at P < 0.05.

3. Results

3.1. Participant characteristics

Participants were recruited in the Acute Medical Assessment Unit (AMAU; n = 44) and the intensive care unit (ICU; n = 6). One of the AMAU patients transferred to the ICU (for 12 days) following baseline measurements. There were 54% males in the cohort and a mean age of 68 ± 17 years (Table 1). The most common comorbidities were cardiovascular diseases, asthma and chronic heart failure. Mean CURB-65 score for the cohort was 1.9; 1.8 for the AMAU patients and 3.5 for the ICU patients (excluding two ICU patients who had transferred from other hospitals and so had lower CURB-65 scores at admission). Mean length of hospital stay (LOS) was 3 days, with a higher mean LOS of 24 days for the ICU cohort. Two of the participants in the AMAU cohort died (of cardiac complications) giving an overall mortality of 4% for the total cohort.
Table 1. Participant baseline characteristics.

| Characteristic | Total cohort (n=50) | AMAU (n=44) | ICU 1 (n=6) |
|----------------|---------------------|-------------|-------------|
| Age (years)    | 68 (17) 2           | 66 (22)     | 58 (17)     |
| Male sex (n, %)| 27 (54)             | 23 (52)     | 4 (67)      |
| Comorbidities (n, %) | COPD 6 (14) | Asthma 11 (25) | Cardiovascular disease 1 (17) |
|                | COPD 1 (17)         | Chronic heart failure 9 (20) | Renal failure 1 (17) |
|                |                     | Cardiovascular disease 19 (43) | Hematological malignancy 1 (17) |
|                |                     | Diabetes 5 (11) | Immune compromised 1 (17) |
|                |                     | Cerebrovascular disease 6 (14) |                          |
|                |                     | Renal disease 3 (7) |                          |
|                |                     | Solid organ malignancy 2 (5) |                          |
|                |                     | Hematological malignancy 1 (2) |                          |
|                |                     | Immune suppression 2 (5) |                          |
| Temperature (°C) | 38 (1.2)           | 147 (33)    | 80 (11)     |
| Hypothermia (n, %) | 2 (4.5)           | 79 (18)     | 46 (10)     |
| Systolic BP     | 139 (38)           | 147 (33)    | 80 (11)     |
| Diastolic BP    | 75 (20)            | 79 (18)     | 46 (10)     |
| Heart rate (beats/min) | 106 (22) | 36 (11)     |              |
| Radiological confirmation (n, %) | 37 (84) | 37 (84)     |              |
| CURB-65 (0-5)   | 1.9 (1.3)          | 1.8 (1.3)   | 3.5 (0.6)   |
| SAPS II (0-163) | 40 (11)            | 20 (6)      |              |
| APACHE II (0-79)| 72 (24)            | 20 (6)      |              |
| APACHE III (0-299) | 10 (3)          | 10 (3)      |              |
| SOFA score (0-24) | 6 (100)        | 6 (100)     |              |
| Vasopressors (n, %) | 0                | 0           | 6 (100)     |
| Mechanical ventilation (n, %) | 0 | 0           |              |
| FiO2           | 0.38 (0.07)        | 3 (0.99)    | 24 (5.99)   |
| Hospital LOS (days) | 3 (0-99)       | 3 (0-91)    | 2 (4.5)     |
| Mortality (n, %) | 2 (4.0)           | 2 (4.5)     | 0           |

1 Two of the ICU patients were transferred from other hospitals and were excluded from CURB-65 calculations; 2 data is presented as mean (SD) unless otherwise indicated; 3 data is presented as median and range. Key: AMAU, Acute Medical Assessment Unit; APACHE, Acute Physiology and Chronic Health Evaluation; COPD, chronic obstructive pulmonary disease; CURB, Confusion Urea Respiratory rate Blood pressure; ICU, intensive care unit; LOS, length of stay; MSQ, Mental Status Questionnaire; NZEWS, New Zealand Early Warning Score; SAPS, Simplified Acute Physiology Score; SOFA, Sequential Organ Failure Assessment.

The ICU cohort exhibited more severe hematological parameters, including a significantly higher mean C-reactive protein concentration ($P = 0.027$; Table 2). *Streptococcus pneumonia* was the most common pathogen identified in the AMAU patients (11%), followed by *Legionella* (9%) and *Haemophilus influenzae* (7%), and 11% of the patients had viral pathogens identified (*Adenovirus, Influenza A, Parainfluenza and Rhinovirus*). Although *Pseudomonas aeruginosa* was the most common pathogen identified in the ICU patients, the role in causing the initial CAP was unclear.
Table 2. Participant hematological parameters.

| Parameter                  | Total cohort (n=50) | AMAU (n=44) | ICU \(^\dagger\) (n=6) |
|----------------------------|---------------------|-------------|------------------------|
| White cell count (x10^9/L) | 13 (6)              | 13 (5)      | 18 (13)                |
| Neutrophils (x10^9/L)      | 11 (5)              | 11 (5)      | 15 (10)                |
| Hemoglobin (g/L)           | 130 (17)            | 130 (17)    | 125 (26)               |
| Platelets (x10^9/L)        | 241 (117)           | 244 (91)    | 218 (227)              |
| Urea (mmol/L)              | 8.4 (6.5)           | 7.4 (4.1)   | 15 (13)                |
| Creatinine (µmol/L)        | 107 (61)            | 98 (29)     | 168 (138)              |
| Bilirubin (µmol/L)         | 19 (11)             | 18 (9)      | 25 (13)                |
| C-reactive protein (mg/L)  | 165 (127)           | 152 (127)   | 261 (78)               |
| Alanine transaminase (U/L) | 34 (21)             | 33 (21)     | 35 (23)                |
| Alkaline phosphatase (U/L) | 112 (53)            |             |                        |
| Lactate (mmol/L)           |                     | 1.5 (0.8)   |                        |
| PaO\(_2\) (mmHg)           |                     | 79 (19)     |                        |
| PaO\(_2\)/FiO\(_2\)       |                     | 212 (59)    |                        |

Key: AMAU, Acute Medical Assessment Unit; ICU, intensive care unit.

3.2. Vitamin C and protein carbonyls

The vitamin C status of community-acquired pneumonia patients admitted to hospital was 23 ± 14 µmol/L; this was significantly lower than healthy controls (56 ± 24 µmol/L; \(P < 0.001\); Figure 1a). The patients admitted to the ICU had significantly lower vitamin C status than those admitted to AMAU (11 ± 3 µmol/L vs 24 ± 14 µmol/L; \(P = 0.02\)). Protein carbonyls, an established biomarker of oxidative stress, were significantly elevated in patients with pneumonia compared with healthy controls (468 ± 305 vs 159 ± 39 pmol/mg protein, respectively; \(P < 0.001\); Figure 1b).

![Figure 1](image1.png)

**Figure 1.** Vitamin C status and protein carbonyl concentrations in the community-acquired pneumonia (CAP) cohort and healthy controls. (a) Vitamin C was measured using HPLC with electrochemical detection; (b) Protein carbonyls were measured using ELISA. Box plots show median with 25th and 75th percentiles as boundaries, and whiskers are the 5th and 95th percentiles, with symbols indicating outlying data points.

The pneumonia cohort comprised 96% patients with inadequate vitamin C status (i.e. <50 µmol/L), 62% with hypovitaminosis C and 22% with frank deficiency (Figure 2). In contrast, the healthy controls comprised only 8% with hypovitaminosis C and no cases of deficiency.
Figure 2. Percentage of individuals from the community-acquired pneumonia (CAP) cohort and healthy controls in different vitamin C categories. Vitamin C categories are presented as: saturating (>70 µmol/L), adequate (between 70 and 50 µmol/L), inadequate (between 50 and 23 µmol/L), hypovitaminosis C (between 23 and 11 µmol/L), deficient (<11 µmol/L).

Subsequent samples were collected from 14 (28%) of the participants (mean 2.7 ± 1.7 days, range 1-7 days); there were no statistically significant differences between baseline and subsequent samples for either vitamin C status or protein carbonyl concentrations (Table 3).

Table 3. Vitamin C status and protein carbonyl concentrations measured over time.

| Biomarker                  | Baseline sample 1 | Second sample 2 | P value |
|----------------------------|-------------------|-----------------|---------|
| Vitamin C (µmol/L)         | 20 (7)            | 22 (7)          | 0.6     |
| Protein carbonyls (pmol/mg protein) | 541 (157)        | 625 (252)       | 0.6     |

1 data expressed as mean (95% CI); 2 mean 2.7 ± 1.7 days (range 1-7 days)

3.3. Biomarker correlations with clinical and physiological parameters

There was no significant correlation between vitamin C status and CURB-65 scores (p = 0.3), however, there was a significant correlation with systolic blood pressure (R = 0.33, p = 0.02) and a trend towards significance with diastolic blood pressure (R = 0.26, p = 0.07). There was no correlation between vitamin C status and C-reactive protein concentrations (R = 0.25, p = 0.09). In contrast, there was a significant correlation between protein carbonyls and the CURB-65 score (R = 0.4, p = 0.006), as well as with urea and creatinine (R = 0.50-0.58, p < 0.001). There was no correlation between protein carbonyls and vitamin C status in the pneumonia cohort (p = 0.3), however, an inverse correlation between protein carbonyls and vitamin C status was observed in the healthy controls (R = -0.38, P = 0.006).

4. Discussion

Our study shows that patients with community-acquired pneumonia have significantly depleted vitamin C status (mean of 23 µmol/L) and a high prevalence of hypovitaminosis C and deficiency (62% and 22%, respectively). Lower vitamin C status was evident with increasing severity of the condition, as shown by the ICU patients having significantly lower vitamin C status than the rest of the hospitalized cohort. Our data is in agreement with two early observational studies investigating vitamin C status in patients with pneumonia [11, 12]. Vitamin C concentrations of 31 µmol/L were reported in 11 patients with pneumonia, compared with concentrations of 66 µmol/L in 20 healthy controls [11]. In a very early study from the 1950s, ascorbate concentrations of 17 µmol/L in 7 acute patients who died, 24 µmol/L in 15 acute survivors and 34 µmol/L in 13 convalescent cases were compared with 49 µmol/L in 28 healthy controls [12]. Thus, this study supports our finding of
lower vitamin C status in more severe cases. These investigators also reported elevated concentrations of oxidized vitamin C (dehydroascorbic acid) in the patient samples, suggesting enhanced oxidative stress, however, the high levels reported in this study are likely an artifact of the assay method used [20].

We were able to collect subsequent samples from a subgroup of the patients, which showed no change in vitamin C status in samples collected up to a week later. This is in agreement with an earlier intervention study by Hunt et al. who reported baseline vitamin C levels of 23 μmol/L in 57 elderly people with pneumonia or bronchitis, while two weeks later levels remained in the hypovitaminosis C range (i.e. 19 μmol/L) in the participants who did not receive vitamin C (n = 29) [13]. Another study also showed hypovitaminosis C in 70 patients with acute pneumonia at days 5 and 10 [14]. By week four, both of these studies reported that vitamin C status was still low and only approaching baseline levels [13, 14]. This indicates that the vitamin C status of patients with pneumonia is likely to remain low for a significant duration following their illness.

In our study we measured protein carbonyls as a marker of oxidative stress. Protein carbonyls can be formed by a variety of reactive oxygen species and via a number of different reaction pathways including direct oxidation of specific amino acids, oxidative cleavage of the protein backbone, or reaction of reactive sugar- and lipid-derived aldehydes with specific amino acids [21]. We found significantly elevated protein carbonyls in the patients with pneumonia compared with healthy controls. Elevated protein carbonyls have been observed previously in critically ill patients with sepsis [22]. The patients with the highest protein carbonyl values in our study had hypovitaminosis C. Interestingly, a pre-clinical animal model indicated that administration of high-dose vitamin C to mice with sepsis decreased protein carbonyl levels in the most severely ill [23]. This has not yet been demonstrated in human studies, however, based on vitamin C’s potent antioxidant properties, it is possible that vitamin C administration to patients with pneumonia could decrease markers of oxidative stress.

Vitamin C is known to have numerous immune supporting functions, including enhancing various leukocyte functions such as chemotaxis and microbial killing (reviewed in [9]). It may also be able to support resolution of the inflammatory process by enhancing neutrophil apoptosis and clearance from the lungs [24, 25], as well as limiting generation of neutrophil extracellular traps (NETs) which are known to enhance and prolong lung inflammation [26, 27]. Although we did not measure the vitamin C content of leukocytes, Hunt et al. have shown that the vitamin C content of leukocytes is low in patients with acute respiratory infections and these remain low at week 2, although some recovery is observed by week 4 [13]. It is possible that these depleted vitamin C levels may affect neutrophil function [9]. The vitamin C content of neutrophils has also been measured during upper respiratory tract infections such as the common cold [28, 29]. Although vitamin C levels do decrease in leukocytes during the common cold, the levels recover more rapidly (i.e. within 4-5 days) than was observed for leukocytes from pneumonia patients. This indicates a prolonged burden on the immune cells of patients with pneumonia, which may affect their recovery.

Surprisingly few vitamin C intervention studies have been carried out in patients with pneumonia. Administration of vitamin C at a dose of 200 mg/d to 28 elderly patients with pneumonia and bronchitis restored saturating vitamin C status within 2 weeks and also improved leukocyte vitamin C concentrations [13]. This study also showed a decreased respiratory symptom score in the most severely ill and a trend towards decreased mortality. Another intervention study showed a dose dependent decrease in duration of hospital stay from 24 d in the control group to 19 days in the lower vitamin C group (250-800 mg/d) and 15 days in the higher vitamin C group (500-1,600 mg/d) [14]. Thus, administration of vitamin C to depleted pneumonia patients may improve their clinical outcomes.

Sepsis is a common complication of severe pneumonia, often requiring admission to the ICU. We have previously shown that critically ill patients with sepsis have depleted vitamin C status despite receiving recommended enteral and parenteral intakes of vitamin C (up to a mean of 200 mg/d) [30]. Other clinical research has indicated that critically ill patients likely need at least 10-fold more vitamin C (i.e. 2-3 g/d) to compensate for the enhanced requirements for the vitamin during the
inflammatory process [31, 32]. Therefore, it is likely that pneumonia patients who have progressed to sepsis and have been admitted to the ICU will require gram intravenous (IV) doses of vitamin C to restore adequate vitamin C status. One trial has shown improved radiologic score and decreased mortality in severe pneumonia cases in the ICU who were administered IV vitamin C at a dose of 6g/d [33]. A number of other clinical trials of patients with sepsis and septic shock have also indicated improved patient outcomes with administration of gram doses of IV vitamin C [10]. The decreased requirement for vasopressor drugs observed in some trials may reflect vitamin C’s ability to aid in endogenous vasopressor synthesis via its enzyme cofactor functions [34]. In support of this premise, we observed a positive correlation between vitamin C status and blood pressure in the patients with pneumonia.

Although the samples in our study were collected prior to the SARS-CoV-2 outbreak, it is likely that people with COVID-19-associated pneumonia and sepsis would have similarly low vitamin C status and high oxidative stress. Early case reports from the 1940s indicated that IV administration of gram doses of vitamin C to cases of viral pneumonia rapidly improved common symptoms [35]. There are currently a number of intervention trials up and running around the world which will specifically test IV vitamin C for COVID-19-related pneumonia and sepsis. Furthermore, it is likely that patients with other severe infectious conditions may also have low vitamin C status. This has been previously demonstrated in patients with tuberculosis, bacterial meningitis, tetanus and typhoid fever [11, 12]. These patients would also likely benefit from additional vitamin C supplementation.

5. Conclusions

Patients with pneumonia exhibit low vitamin C status and an elevated prevalence of hypovitaminosis C and deficiency compared with healthy controls. This indicates an enhanced requirement for the vitamin during their illness. Due to the important roles that vitamin C plays in the immune system, low vitamin C status is possibly both a cause and a consequence of the disease. The patients also exhibited elevated oxidative stress as evidence by significantly higher protein carbonyl concentrations than healthy controls. Therefore, these patients would likely benefit from additional vitamin C supplementation to restore their blood and tissue levels to optimal. This may decrease oxidative stress and aid in their recovery.

Author Contributions: Conceptualization, A.C., S.C.; methodology, S.C., E.S.; investigation, L.D., E.S.; data curation, L.D., A.C.; formal analysis, A.C.; writing—original draft preparation, A.C.; writing—review and editing, S.C., E.S., L.D.; supervision, A.C., S.C.; project administration, A.C.; funding acquisition, A.C.

Funding: This research was funded by the Health Research Council of New Zealand (grant number 16/037) and the Canterbury Medical Research Foundation (grant number 15/06).

Acknowledgments: AC is a recipient of a Sir Charles Hercus Health Research Fellowship from the Health Research Council of New Zealand. Thank you to Bruce Dobbs for setting up the patient database, Marguerite DeAbaffy for helping to recruit patients and collect blood samples, and Kate Vick for processing the patient samples.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Musher DM, Thorner AR. Community-acquired pneumonia. N Engl J Med. 2014;371(17):1619-28.
2. Lai CC, Liu YH, Wang CY, Wang YH, Hsueh SC, Yen MY, Ko WC, Hsueh PR. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. J Microbiol Immunol Infect. 2020.
3. GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1151-210.

4. GBD 2016 Lower Respiratory Infections Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis. 2018;18(11):1191-210.

5. Burton DC, Flannery B, Bennett NM, Farley MM, Gershman K, Harrison LH, Lynfield R, Petit S, Reingold AL, Schaffner W, Thomas A, Plikaytis BD, Rose CE Jr., Whitney CG, Schuchat A. Socioeconomic and racial/ethnic disparities in the incidence of bacteremic pneumonia among US adults. Am J Public Health. 2010;100(10):1904-11.

6. Chambers S, Laing R, Murdoch D, Frampton C, Jennings L, Karalus N, Mills G, Town I. Maori have a much higher incidence of community-acquired pneumonia and pneumococcal pneumonia than non-Maori. N Z Med J. 2006;119(1234):U1978.

7. Hemilä H. Vitamin C and infections. Nutrients. 2017;9(4):E339.

8. Myint PK, Wilson AM, Clark AB, Luben RN, Wareham NJ, Khaw KT. Plasma vitamin C concentrations and risk of incident respiratory diseases and mortality in the European Prospective Investigation into Cancer-Norfolk population-based cohort study. Eur J Clin Nutr. 2019;73(11):1492-500.

9. Carr AC, Maggini S. Vitamin C and immune function. Nutrients. 2017;9(11):E1211.

10. Carr AC. Vitamin C in pneumonia and sepsis. In: Chen Q, Vissers M, editors. Vitamin C: New Biochemical and Functional Insights. Oxidative Stress and Disease. Boca Raton, FL CRC Press/Taylor & Francis; 2020. p. 115-35.
19. Buss H, Chan TP, Sluis KB, Domigan NM, Winterbourn CC. Protein carbonyl measurement by a sensitive ELISA method. Free Radic Biol Med. 1997;23(3):361-6.

20. Pullar JM, Bayer S, Carr AC. Appropriate handling, processing and analysis of blood samples is essential to avoid oxidation of vitamin C to dehydroascorbic acid. Antioxidants. 2018;7(2):E29.

21. Weber D, Davies MJ, Grune T. Determination of protein carbonyls in plasma, cell extracts, tissue homogenates, isolated proteins: Focus on sample preparation and derivatization conditions. Redox biology. 2015;5:367-80.

22. Winterbourn CC, Buss IH, Chan TP, Plank LD, Clark MA, Windsor JA. Protein carbonyl measurements show evidence of early oxidative stress in critically ill patients. Crit Care Med. 2000;28(1):143-9.

23. Kim J, Arnaout L, Remick D. Hydrocortisone, ascorbic acid and thiamine (HAT) therapy decreases oxidative stress, improves cardiovascular function and improves survival in murine sepsis. Shock. 2019.

24. Vissers MC, Wilkie RP. Ascorbate deficiency results in impaired neutrophil apoptosis and clearance and is associated with up-regulation of hypoxia-inducible factor 1alpha. J Leukoc Biol. 2007;81(5):1236-44.

25. Fisher BJ, Kraskauskas D, Martin EJ, Farkas D, Wegelin JA, Brophy D, Ward KR, Voelkel NF, Fowler AA, 3rd, Natarajan R. Mechanisms of attenuation of abdominal sepsis induced acute lung injury by ascorbic acid. Am J Physiol Lung Cell Mol Physiol. 2012;303(1):L20-L32.

26. Mohammed BM, Fisher BJ, Kraskauskas D, Farkas D, Brophy DF, Fowler AA, Natarajan R. Vitamin C: a novel regulator of neutrophil extracellular trap formation. Nutrients. 2013;5(8):3131-51.

27. Bozonet SM, Carr AC. The role of physiological vitamin C concentrations on key functions of neutrophils isolated from healthy individuals. Nutrients. 2019;11(6).

28. Hume R, Weyers E. Changes in leucocyte ascorbic acid during the common cold. Scott Med J. 1973;18(1):3-7.

29. Wilson CW. Ascorbic acid function and metabolism during colds. Ann N Y Acad Sci. 1975;258:529-39.

30. Carr AC, Rosengrave PC, Bayer S, Chambers S, Mehrtens J, Shaw GM. Hypovitaminosis C and vitamin C deficiency in critically ill patients despite recommended enteral and parenteral intakes. Crit Care. 2017;21:300.

31. Long CL, Maull KI, Krishnan RS, Laws HL, Geiger JW, Borghesi L, Franks W, Lawson TC, Sauberlich HE. Ascorbic acid dynamics in the seriously ill and injured. J Surg Res. 2003;109(2):144-8.

32. de Grooth HJ, Manabulu-Choo WP, Zandvliet AS, Spoelstra-de Man AME, Girbes AR, Swart EL, Oudemans-van Straaten HM. Vitamin-C pharmacokinetics in critically ill patients: a randomized trial of four intravenous regimens. Chest. 2018;153(6):1368-77.

33. Kim WY, Jo EJ, Eom JS, Mok J, Kim MH, Kim KU, Park HK, Lee MK, Lee K. Combined vitamin C, hydrocortisone, and thiamine therapy for patients with severe pneumonia who were admitted to the intensive care unit: Propensity score-based analysis of a before-after cohort study. J Crit Care. 2018;47:211-8.

34. Carr AC, Shaw GM, Fowler AA, Natarajan R. Ascorbate-dependent vasopressor synthesis: a rationale for vitamin C administration in severe sepsis and septic shock? Crit Care. 2015;19:e418.

35. Klenner FR. Virus pneumonia and its treatment with vitamin C. South Med Surg. 1948;110(2):36-8.